Cardiff Oncology, Inc. (CRDF)

NASDAQ: CRDF · USD

$0.93

+0.05 (+6.3%)· Recorded snapshot

Market cap	72.3M
Revenue (ttm)	508K
Net income (ttm)	-40.1M
EPS (ttm)	-$0.59
Shares out	77.8M
Volume	266,877
Beta	1.42

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 508K
Net income (ttm): -40.1M
EPS (ttm): -$0.59
Market cap: 72.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-94.1

P25 n/aP50 n/aP75 n/a

ROIC-60.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CRDF indicators

Market & fundamental data

Available fields

208

Groups with data

Currency

USD

Showing 208 of 208 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001213037
Company name	Cardiff Oncology, Inc.
Country	United States
Country code	US
CUSIP number	14147L108
Earnings date	2026-11-09
Earnings time	amc
Employees	31
Employees change	-2
Employees growth	-6.06%
Enterprise value	$38.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1999
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US14147L1089
Last 10-K release date	2026-02-24
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split date	2019-02-20
Last stock split type	Reverse
Market cap	$72.3M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$0.93
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	CRDF
U.S. state	California
Website	https://www.cardiffoncology.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-63.6%
EV/Sales	68.98x
FCF / EV yield	-116.76%
FCF yield	-59.21%
Forward EV/Sales	98.91x
Forward P/S	195.05x
P/B ratio	2.26x
P/S ratio	136.03x
Price / tangible book value	2.6x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-8,320.08%
Pretax margin	-7,884.06%
Profit per employee	$-1.3M
Revenue per employee	$16,387
ROA	-46.73%
ROA (5Y)	-26.53%
ROCE	-159.3%
ROE	-94.08%
ROE (5Y)	-46.09%
ROIC	-60.88%
SBC / revenue	1,028.54%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	6
EPS growth years	1
Gross profit growth (Q)	-14.05%
Net income growth quarters	4
Net income growth years	0
Revenue growth	-6.79%
Revenue growth (Q)	-14.05%
Revenue growth (QoQ)	153.66%
Revenue growth 10Y	3.49%
Revenue growth 3Y	7.23%
Revenue growth 5Y	5.11%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-62,000
Depreciation and amortization	$351,000
EBIT	$-42.3M
EBITDA	$-41.9M
EPS	$-0.59
FCF per share	$-0.53
Financing cash flow	$2.8M
Free cash flow	$-40.9M
Free cash flow minus SBC	$-46.1M
Gross profit	$-34.8M
Investing cash flow	$36.4M
Net cash flow	$-1.6M
Net income	$-40.1M
Operating cash flow minus SBC	$-46.1M
Operating income	$-42.3M
Revenue	$508,000
Stock-based compensation	$5.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-11.68
Book value per share	$0.39
Debt / equity	0.02
Long-term assets	$1.7M
Long-term liabilities	$0
Net cash (debt)	$34.1M
Net cash / market cap	49.29%
Net cash growth	-51.18%
Net debt / equity	-1.28
Piotroski F-Score	1
Property, plant and equipment	$810,000
Shareholders' equity	$26.5M
Tangible book value	$26.5M
Tangible book value per share	$0.39
Total assets	$37.3M
Total cash	$34.5M
Total debt	$457,000
Total liabilities	$10.8M
WACC	11.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	$35.6M
Current liabilities	$10.8M
Current ratio	3.3
Net working capital	$-9.3M
Quick ratio	3.21
Working capital	$24.8M
Working capital turnover	0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-15.77%
Dividend yield	0%
Shareholder yield	-15.77%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.68%
10Y return CAGR	-43.73%
10Y total return	-99.68%
150-day SMA	$1.29
15Y price change	-99.68%
15Y return CAGR	-31.78%
15Y total return	-99.68%
1D price change	6.26%
1M price change	-27.01%
1M total return	-27.01%
1W price change	-2.83%
1W total return	-2.83%
1Y price change	-60.48%
1Y return CAGR	-60.5%
1Y total return	-60.48%
20-day SMA	$0.99
200-day SMA	$1.46
20Y price change	-99.71%
20Y return CAGR	-25.37%
20Y total return	-99.71%
3M price change	8.28%
3M total return	8.28%
3Y price change	-13.8%
3Y return CAGR	-4.83%
3Y total return	-13.8%
50-day SMA	$1.08
50-day SMA vs 200-day SMA	50under200
52-week high	$3.31
52-week high date	2025-12-26
52-week low	$0.76
52-week low date	2026-07-29
5Y price change	-84.48%
5Y return CAGR	-31.11%
5Y total return	-84.48%
6M price change	-47.38%
6M total return	-47.38%
All-time high	$2,030.40
All-time high date	2005-06-08
All-time low	$0.70
All-time low date	2020-03-19
Average true range (ATR)	$0.08
Average volume	444.9K
Beta (1Y)	3.04
Beta (2Y)	1.28
Beta (5Y)	1.42
Change from 52-week high	-71.91%
Change from 52-week low	22.91%
Change from all-time high	-99.96%
Change from all-time low	29.12%
Change from open	8.24%
Day's gap	-1.83%
Dollar volume	$248,169
High price	$0.93
Low price	$0.86
Monthly RSI	39.42
Open price	$0.86
Position in 52-week range	100%
Premarket change	2.83%
Premarket close	$0.88
Premarket price	$0.90
Premarket volume	792
Previous close	$0.88
Price vs 150-day SMA	-29.73%
Price vs 20-day SMA	-8.63%
Price vs 200-day SMA	-37.88%
Price vs 50-day SMA	-16.27%
Relative volume	0.6
RSI	39.83
Sharpe ratio	-0.65
Sharpe ratio (3Y)	0.42
Sharpe ratio (5Y)	0.07
Sortino ratio	-0.76
Sortino ratio (3Y)	0.75
Sortino ratio (5Y)	0.17
Volume	266.9K
Weekly RSI	38.18
YTD price change	-67.79%
YTD total return	-67.79%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	75.4M
Float percentage	96.9%
Shares change (QoQ)	0.07%
Shares change (YoY)	15.77%
Shares held by insiders	3.1%
Shares held by institutions	25.03%
Shares outstanding	77.8M
Short % of float	16.08%
Short % of shares	15.58%
Short ratio	14.2 days

Deeper analysis on CRDF

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CRDF report

Is a complete CRDF research report available?

No complete published report is available for Cardiff Oncology, Inc. (CRDF) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cardiff Oncology, Inc. (CRDF)

Price

Financial snapshot

Fair-value bridge

Latest news · CRDF

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CRDF indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CRDF

Frequently asked questions